May 17th 2024
Scassellati Sforzolini discusses the significance of Galderma’s nemolizumab receiving 4 additional filing acceptances for prurigo nodularis and atopic dermatitis.
Advances In: Integrating New Treatment Options into Management Plans for Patients with Moderate-to-Severe Atopic Dermatitis
View More
Medical Crossfire®: Maximizing Patient Outcomes in Shingles – Are You Leveraging Guideline Based Care?
View More
"REEL" Time Patient Counseling™: Integrating Biosimilars into the Clinical Conversation
View More
PER Skin Summit: Optimizing Diagnosis and Individualizing Management of Hidradenitis Suppurativa
View More
Community Practice Connections™: 19th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
View More
Expert Illustrations & Commentaries™: A Deeper Look at the Pathogenesis of Hidradenitis Suppurativa (HS)
View More
Cancer Summaries and Commentaries™: Clinical Updates in Melanoma from Philadelphia
View More
Expert Illustrations & Commentaries™: Picturing the Potential Role of OX40 and OX40L Inhibitors in Atopic Dermatitis
View More
Hidradenitis Suppurativa (HS): Deepening Foundations of Knowledge in Disease Pathogenesis, Disease Severity Assessment, and Treatment Decision-Making
View More
A game-changer for children with atopic dermatitis
April 26th 2019“Pretty much, I couldn’t go about my normal life,” says Benjamin Sun about a life-altering eczema flare up at age 9, which left him out of school and bedridden for weeks. Until now, children like Sun didn’t have an effective, safe option for long-term disease control. Read how dupilumab changed his quality of life, and what it can do for your pediatric patients with uncontrolled moderate to severe atopic dermatitis.
JAK inhibitors offer multiple applications
March 21st 2019Unlike prior generations of dermatologic drugs, Janus kinase (JAK) inhibitors show potential for treating numerous dermatologic indications. Brett King, M.D., Ph.D. explored what this class of drug has to offer in his presentation during AAD earlier this month.
Atopic dermatitis treatments move beyond one-size-fits-all
March 21st 2019In the future, atopic dermatitis (AD) may need to be targeted with different drugs and tailored for different AD populations, particularly if initial treatment targeting all phenotypes fails, says Emma Guttman-Yassky, M.D., Ph.D.
New biologics target a number of dermatoses
March 3rd 2019The development of new biologics targeting a variety of dermatoses is on the upswing with some treatments coming to the clinic as early as this year, according to April Armstrong, M.D. who discussed the topic at the American Academy of Dermatology Spring Meeting in Washington, D.C.
Skin issues that affect patients with skin of color
February 6th 2019Healthcare disparities exist in all fields of medicine, including dermatology. We seek to address these disparities in this article by outlining the differences in epidemiology, presentation, access and outcomes of five conditions in patients with skin of color.
Laundry soap earns stamp of approval for sensitive skin
January 3rd 2019The National Psoriasis Foundation and the National Eczema Association have awarded Procter & Gamble’s Tide Free and Gentle Liquid Laundry Detergent and Tide PODS Free and Gentle Laundry Detergent a “Seal of Recognition” and “Seal of Acceptance” for people with eczema or sensitive skin.
Top 10 dermatology stories of 2018
December 19th 2018Before 2018 comes to a close, we wanted to say thank you to our readers from everyone here at Dermatology Times. As a thank you, we have compiled a list of the topics and issues you found most compelling throughout the year. Enjoy this slideshow - and see you in 2019!